Belantamab eliminates MM cells by (1) triggering cell-cycle arrest through MMAF inhibition of the microtubule network, (2) inhibiting BAFF/APRIL binding to BCMA and downstream NF-κB activation, and (3) enhancing ADCC [51]. Here, TNFSF13B is linked to Miyoshi myopathy.